Cancer Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
24
NCT04120246
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 8, 2020
Completion: Feb 1, 2030
Loading map...